Related Experiment Video
Updated: Nov 21, 2025
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Clinical perspectives on ischemic stroke
Atsushi Mizuma1, Midori A Yenari2
1Department of Neurology, University of California, San Francisco and the San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA; Department of Neurology, Tokai University School of Medicine, Isehara, Japan.
Abstract:
Treatments for acute stroke have improved over the past years, but have largely been limited to revascularization strategies. The topic of neuroprotection, or strategies to limit brain tissue damage or even reverse it, has remained elusive. Thus, the clinical mainstays for stroke management have focused on prevention. The lack of clinical translation of neuroprotective therapies which have shown promise in the laboratory may, in part, be due to a historic inattention to comorbidities suffered by a majority of stroke patients. With the advent of more stroke models that include one or more relevant comorbidities, it may be possible to identify effective treatments that may translate into new treatments at the clinical level. In the meantime, we review comorbidities in stroke patients, modification of stroke risk factors and available acute stroke treatments in the clinic.
Insights
Neuroprotection strategies for acute stroke remain elusive, hindering clinical translation. Incorporating comorbidities into stroke models may unlock new treatments for brain tissue protection.
Area of Science:
- Neurology
- Neuroscience
- Clinical Medicine
Background:
- Acute stroke treatments have advanced, primarily through revascularization.
- Neuroprotection strategies to limit or reverse brain damage have not translated effectively to clinical practice.
- Current stroke management heavily relies on prevention due to the lack of successful neuroprotective therapies.
Purpose of the Study:
- To review the role of comorbidities in stroke patients.
- To discuss the modification of stroke risk factors.
- To outline currently available acute stroke treatments.
Main Methods:
- Review of existing literature on stroke comorbidities.
- Analysis of stroke risk factor modification strategies.
- Summary of current clinical treatments for acute stroke.
Main Results:
- Neuroprotection has been a challenging area in stroke research.
- Comorbidities in stroke patients have historically been overlooked in treatment development.
- Newer stroke models incorporating comorbidities show promise for identifying translatable therapies.
Conclusions:
- Effective clinical translation of neuroprotective therapies requires addressing patient comorbidities.
- Further research using comorbidity-inclusive stroke models is crucial.
- Understanding and managing comorbidities is key to advancing acute stroke care.
More Related Videos
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:23Atherosclerosis IV: Nursing Management
01:27Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations